

Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited and Hong Kong Securities Clearing Company Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Beijing Luzhu Biotechnology Co., Ltd.

北京綠竹生物技術股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2480)

VOLUNTARY ANNOUNCEMENT BUSINESS UPDATE – COMPLETION OF ENROLLMENT OF SUBJECTS FOR PHASE III CLINICAL TRIAL OF LZ901 IN THE PRC

This announcement is made by Beijing Luzhu Biotechnology Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders of the Company and potential investors on the latest business updates of the Group.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that LZ901, the core product of the Group, has completed the enrollment of subjects for its Phase III clinical trial in the People’s Republic of China (the “**PRC**”), and more than 98% subjects have received two doses of LZ901 injection or placebo injection, as the case may be. The Phase III clinical trial will now proceed to case collection, and will proceed to interim unblinding work of the trial data after the primary endpoints of the trial are being met.

The Phase III clinical trial is a multi-center, randomized, double-blind, placebo-controlled parallel study to evaluate the efficacy and safety profile of LZ901 for the prevention of herpes zoster in adults aged 40 years and older. The study is conducted in four provinces including Jiangsu, Shandong, Hubei and Shanxi, with a total enrollment of 26,000 healthy subjects aged 40 years and older as of the date of this announcement.

ABOUT LZ901

LZ901 is a recombinant herpes zoster vaccine candidate independently developed by the Group, and is the core product of the Group. It is developed based on the varicella-zoster virus (“**VZV**”) glycoprotein E-fragment crystallizable region, and has a tetrameric molecular structure to prevent shingles caused by VZV. LZ901 is designed on the basis of making full use of the mechanism of the human immune system for processing foreign antigens, and prevents the occurrence of herpes zoster and related complications caused by herpes zoster, including postherpetic neuralgia.

ABOUT THE COMPANY

The Company is a biotechnology company committed to developing innovative human vaccines and therapeutic biologics to prevent and control infectious diseases and treat cancer and autoimmune diseases. Since its inception in 2001, the Company has focused on human medicine and has established technology platforms with its understanding of immunology and protein engineering, which empowers the Company to develop its recombinant vaccine and antibody product candidates with favorable efficiency, high purity and improved stability.

Cautionary statement required by Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: The Company cannot guarantee that LZ901 will ultimately be successfully developed and marketed. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Beijing Luzhu Biotechnology Co., Ltd.
Mr. KONG Jian
Chairman and Executive Director

Hong Kong, January 18, 2024

As of the date of this announcement, the Board comprises Mr. KONG Jian, Ms. JIANG Xianmin and Ms. ZHANG Yanping as executive Directors; Mr. MA Biao and Mr. KONG Shuangquan as non-executive Directors; and Mr. LEUNG Wai Yip, Mr. LIANG Yeshe and Ms. HOU Aijun as independent non-executive Directors.